Intestinal Methanogen Overgrowth (IMO) More Prevalent than SIBO in Parkinson’s disease with Constipation: Preliminary Results
Objective: Our aim is to quantify the prevalence of small intestinal bacterial overgrowth (SIBO) and intestinal methanogen overgrowth (IMO) in PD subjects with constipation compared…Urinary Symptoms and Parkinson’s Disease: The Patient’s Perspective
Objective: To learn about prevalence rates and the impact of urinary symptoms on day-to-day function and quality of life from the patient’s perspective. Background: Urinary…Movement Disorders After Bariatric Surgeries – Case Series
Objective: Our objective is to report 6 cases series of MD after Bariatric surgeries (BS) and one case after hiatal surgery, with BS behavior. Background:…Effectiveness of lead position with microelectrode recording based support vector machine for characterizing the sub-cortical-structures via deep brain stimulus in Parkinson`s disease
Objective: To develop artificial intelligence(AI) machine/deep learning techniques for processing/analyzing MER signals of STN which will help the surgical-team (neurologists,neurosurgeons) for deciding optimal location of…Video-to-Home Cognitive-Behavioral Therapy for Veterans with Depression and Parkinson’s Disease: A Randomized Controlled Trial
Objective: For the nearly 100,000 veterans with Parkinson’s disease (PD) receiving Veterans Affairs (VA) health care, depression is prevalent, yet often undiagnosed or undertreated. This…Mental Health Matters Too – Integration of physical and mental health in a multidisciplinary Parkinson’s Clinic
Objective: The overall aim of the project was to demonstrate that people with Parkinson’s disease benefit from good mental health care when mental health services…Effect of Combined Modality Treatment on Sustained Phonation in Parkinson’s Disease
Objective: To determine whether Lee Silverman Voice Treatment (LSVT-LOUD(R)) combined with Transcranial Magnetic Stimulation in individuals with Parkinson's disease (PD) improves phonation to a greater…Pridopidine for the treatment of Levodopa-induced Dyskinesia in patients with Parkinson’s disease
Objective: To assess the efficacy and safety of pridopidine in PD patients with Levodopa-induced dyskinesia (LID). Background: Pridopidine is a small molecule in clinical development…Phase I-II first-in-human clinical study of intraputamenal CDNF in Parkinson’s disease: Exploratory PET imaging endpoints of the 12-month treatment period
Objective: To test if intermittent intraputamenal monthly infusions of CDNF have an effect on striatal dopamine transporter (DAT) binding, as measured by PET, in subjects…CHIEF-PD: Cholinesterase Inhibitor to prEvent Falls in Parkinson’s Disease
Objective: Preventing falls in people with Parkinson’s disease has the potential to reduce hospital admissions and improve quality of life by diminishing the significant morbidity…
- « Previous Page
- 1
- …
- 73
- 74
- 75
- 76
- 77
- …
- 149
- Next Page »